Chapter

Assessment of treatment options in renal cancer

Martin Gore and Sheeba Irshad

in Renal Cancer

Published on behalf of Oxford University Press

ISBN: 9780199562312
Published online September 2011 | e-ISBN: 9780199607402 | DOI: http://dx.doi.org/10.1093/med/9780199562312.003.0003

Series: Oxford Oncology Library

Assessment of treatment options in renal cancer

Show Summary Details

Preview

• Several models have been developed as prognostic tools to select patients for treatment strategies, analyse results of clinical trials, and give information to patients regarding prognosis • For localized and locally advanced tumours, surgery is the gold standard • Observation remains standard of care after nephrectomy but results of current adjuvant phase III trials are awaited • Published phase III trials have established the novel targeted agents as standard of care for patients with metastatic renal cell carcinoma (mRCC) • Only selected patients with mRCC, revealing a good-risk profile, and clear cell subtype histology have any chance of deriving clinical benefit from immunotherapy.

Chapter.  5073 words.  Illustrated.

Subjects: Clinical Oncology

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.